WIN General Assembly unanimously elects EORTC member of consortium
13 Jan 2014
The WIN (Worldwide Innovative Networking in personalized cancer medicine) Consortium General Assembly unanimously voted adhesion of the EORTC to the WIN Consortium.
WIN Consortium is a non-profit global collaboration of leading academic, industry, healthplan and advocacy organizations. It focusses its efforts on running global research projects to identify biomarkers for targeted therapies as well as clinical trials to investigate targeted cancer treatments.
Dr. Vladimir Lazar, Chief Operating Officer of the WIN Consortium, warmly welcomed the EORTC to the consortium. The EORTC joins DKFZ (Deutsches Krebsforschungszentrum) and AstraZeneca and new WIN Consortium members.
Dr. Francoise Meunier, EORTC Director General, says, “It is certainly a great step forward for the EORTC to join WIN. We are very enthusiastic about such a productive collaboration within the consortium and to developing exciting joint projects for the benefit of patients with cancer. We find that the mission of WIN to accelerate the pace and reduce the cost of translating the most promising innovations in personalized cancer medicine into the standard of care worldwide, aligns well with that of the EORTC, to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life.”
The upcoming WIN 2014 Symposium on 23 – 24 June 2014 in Paris will focus on breakthrough biomarker investigations and combination therapies for cancer.
John Bean, PhD
EORTC, Medical Science Writer
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023